Your browser doesn't support javascript.
Efficacy of amlodipine besylate and Valsartan for the treatment of mild to moderate hypertension.
Medicine (Baltimore) ; 98(26): e16264, 2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31261595
ABSTRACT

BACKGROUND:

Clinical researchers found that Amlodipine besylate and Valsartan (ABVS) can effectively treat mild to moderate hypertension (MMH). However, no study has systematically investigated its efficacy and safety for patients with MMH. Thus, present study will systematically assess the efficacy and safety of ABVS for patients with MMH.

METHODS:

MEDICINE, Cochrane Library, EMBASE, Ovid, PsycINFO, Web of Science, Allied and Complementary Medicine Database, and China National Knowledge Infrastructure will be searched for literatures related to the topic from inception to the present without language limitations. All randomized controlled trials that assess the efficacy and safety of ABVS for patients with MMH will be considered for inclusion. Two researchers will independently select study, extract data, and assess risk of bias for all eligible studies.

RESULTS:

The primary outcome includes the change of seated diastolic blood pressure. The secondary outcomes consist of the change of seated systolic blood pressure, health-related quality of life, and the tolerability.

CONCLUSIONS:

The results of this study will summarize the latest evidence on ABVS for the treatment of MMH.ETHICS AND DISSEMINATION: This study does not need ethical approval, because it will not use individual data. The results of this study are expected to be published at peer-reviewed journals.PROSPERO REGISTRATION NUMBER: PROSPERO CRD42019133123.
Asunto(s)

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Combinación Amlodipino y Valsartán / Hipertensión / Antihipertensivos Aspecto clínico: Etiología / Terapia Límite: Humanos Idioma: Inglés Revista: Medicine (Baltimore) Año: 2019 Tipo del documento: Artículo País de afiliación: China